Thesan Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin.
Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.
Our lead drug candidates are first-in-class molecules with novel mechanisms of action. Initial target indications include atopic dermatitis (AD) and acne. In both of these areas, there has been a dearth of fundamentally new treatment approaches for decades. Acne is the most common skin disorder in the United States, affecting some 40 to 50 million Americans, with an estimated 85% of all people having acne at some point in their lives. Acne is associated with significant psychosocial and emotional impact, in addition to potential for long term scarring when severe. Atopic dermatitis is a form of eczema where permeability barrier dysfunction leads to itchy, red, and flaky skin, most often starting early in childhood and occasionally persisting as an adult. The prevalence of AD has tripled in the last 30 years and is now experienced by at least 2% of adults and 20% of children in industrialized nations. Significant side effects limit the utility of currently available treatment options.
Thesan Management has an expansive breadth of relevant sector experience having previously held executive positions in leading biopharmaceutical companies, and is backed by first tier investors: Novartis Venture Funds, SV Life Sciences and Lundbeckfonden Ventures.